Two therapies for prostate cancer are among a range of oncology drugs recommended for PBS listing at the November meeting of the Pharmaceutical Benefits Advisory Committee (PBAC). Apalutamide (Erlyand) was recommended for the treatment of patients with non-metastatic castration resistant prostate cancer. The PBAC said was satisfied that “apalutamide provides, for some patients, a moderate ...
Two prostate cancer therapies in latest round of PBAC approvals for oncology
By Michael Woodhead
11 Jan 2022